Panlin Capital Hosts Biopharma Portfolio Empowerment Forum: Charting Diversified Development Paths for China's Innovative Drug Companies
VCBeat
Internet Medical Health Media
Ribo Life Science
Small Nucleic Acid Drug Developer
EndoCell
Developer of in vitro regeneration technology for human tissues and organs
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
May 10,Panlin Capital Biomedical Investment Post-Empowerment Special Forum——“Achieving High-Quality Vitality! The Diversified Development Path of China's Innovative Pharmaceutical Companies"Successfully held. This isPanlin CapitalUnitedVCBeatDuring the "2025 VBEF Future Healthcare 100 Exhibition"In-depth Seminar Planned by Panlin Portfolio, and invited founders of relevant companies, senior investors, and strategic leaders of multinational pharmaceutical enterprises to attend the event. They will also discuss topics such as independent innovation and global development in China's innovative drug industry.
As the organizer,Li Yuhui, Founding Managing Partner of Panlin CapitalExpress welcome to the arriving guests and also to the co-organizers.VCBeatAnd supporting unitsRehabilitation CapitalExpressed gratitude. He stated that the forum planned by Panlin is based on the critical "tipping point" of China's innovative drug industry development, and he hopes to collaborate with outstanding medicalFounders of industries, especially innovative drug R&D companies, and venture capital professionals jointly discussed the high-quality development path for China's innovative drug companies in an era of uncertainty. He also stated that despite the recent capital winter faced by the biopharmaceutical industry, continuous innovations have emerged, and the industry is thriving.The Clinical Value and Commercial Boundaries of China's Innovative Drugs Continue to Expand. This, together with the cold spell in the capital market, constitutes aScissors Gap. From an investment perspective,Now is the best time to invest in the biopharmaceutical industry.。
Founder and Managing Partner of Panlin Capital, Li Yuhui
Founder of Ribo Life Science, Liang ZicaiProfessorPublished an article titled "Global Trends in the Small Nucleic Acid Pharmaceutical Industry —— Ribo Life Science's International Layout"Professor Liang pointed out in his speech on the theme 'Small nucleic acid drugs bring about a revolution in the modern pharmaceutical field and form the third wave of modern pharmaceuticals with their tremendous advantages in high drugability, high R&D speed, and ultra-long efficacy. The next 10 to 20 years will be the golden period for the R&D of small nucleic acid drugs. China has already established a globally competitive research and development foundation in the field of small nucleic acid drugs. In this strategic emerging field, our country has the opportunity to build an ‘electric vehicle-style’ advantage for overtaking in a different lane.'"
Founder of Ribo Life Science, Professor Zicai Liang
EndoCell Founder Professor Cheng XinPublished an article titled "Tissue Replacement Therapy Paradigm —— Regenerative Islet Transplantation for Curing Diabetes"The theme speech. He pointed out that 'EndoCell has achieved positive results in curing Type II and Type I diabetes in autologous and allogeneic IIT patients using regenerated islets prepared with endodermal stem cell technology. EndoCell's ultimate goal is to become a pioneer and leader in the field of tissue and organ regeneration by curing diseases through natural methods.'"
Founder of EndoCell, Professor Cheng Xin
In addition, for the presentThe innovative drug formats and development pathways continuously explored by China's innovative pharmaceutical companies, Panlin Capital also collaborates with its invested companies in the Panlin system on "China's Innovative Pharmaceutical Companies BD Gains Momentum”、“How Can China's CGT Move Towards Commercialization?" and other topics for in-depth discussion.
In "BD Momentum: Chinese Innovative Pharmaceutical Companies Continue to Unlock Greater Value"In the roundtable discussion, the guests unanimously believed that,BDHas becomeAn important way for Chinese innovative pharmaceutical companies to accelerate pipeline progress and even achieve profitability by obtaining cash flow. In the process of advancing BD cooperation,Chinese Innovative Pharmaceutical EnterprisesTo have"Open and Win-Win"The mindset, and take the initiative to connect cooperative resources。And a successful deal should also have the effect ofWin-win,This is also the key for the product to continue moving forward.。
In “Growing Pains: Challenges and Responses in the Commercialization Process of China's CGT Industry"In the roundtable discussion, the guests discussed products related to the CGT field.The commercialization prospect is optimistic,BelieveIn the next 3-5 years, products from Chinese pharmaceutical companies will be approved for marketing in related细分 fields.. It was also pointed out that the premise of commercialization isMakeGood MedicineCome, and then integrate the system through various measuresGradually reduce the cost. From the perspective of each company's product development strategy, everyone isLayout its own product line based on the rigid needs of clinical practice and commercial feasibility.。